INTRODUCTION {#s1}
============

Pancreatic neuroendocrine neoplasms (pNENs), also known as pancreatic endocrine tumors, islet cell neoplasms or islet cell carcinomas, are rare tumors with an annual incidence of 0.19/100,000--0.32/100,000 \[[@R1]--[@R3]\]. However, compared to 1973, the incidence of NENs in 2004 has increased 382% in United States \[[@R3]\]. Although pNENs are associated with relatively indolent physiological behavior, most patients eventually succumb to mortality due to the disease \[[@R4], [@R5]\].

Lymph node metastasis is commonly used as a critical prognostic factor for predicting survival and disease progression of pancreatic ductal adenocarcinomas (PDAC) and pNENs \[[@R6]--[@R9]\]. However, some studies showed that lymph node metastasis was not an independent prognostic factor of PDAC and pNENs \[[@R10], [@R11]\]. The accuracy of staging lymph node was directly proportional to the number of examined lymph nodes (ELNs), and many studies suggested that the extent of ELNs was significantly associated with survival of PDAC, especially in patients without lymph node metastasis \[[@R12]--[@R14]\]. Moreover, lymph node ratio (LNR), the number of metastatic lymph nodes divided by the total number of ELNs, was increasingly recognized as a more powerful prognostic factor than lymph node metastasis in PDAC \[[@R10], [@R11], [@R15]\], intraductal papillary mucinous \[[@R16]\], and ampullary carcinoma \[[@R17], [@R18]\].

However, the benefit of ELNs in pNENs is still unclear; and the role of LNR in predicting survival is contradictory. Boninsegna et al. \[[@R19]\] and Ricci et al. \[[@R20]\] proposed that LNR \> 0.20 and LNR \> 0.07, respectively, was the robust predictor of recurrence of pNENs. On the other hand, Murakami et al. \[[@R8]\] found that LNR \> 0.20 did not correlate with poor overall survival (OS). These contradictory results might be attributed to the relative rarity of the samples and the cut-off values of LNR in these studies, which limited the identification of LNR in survival.

The Surveillance, Epidemiology, and End Results (SEER) database is an authoritative source of information with high-quality cancer registries, established in 1973, encompassing approximately 28% of the USA population. All the malignant cases were followed-up annually to determine the vital status. The large population and completed follow-up of SEER program can be safely speculated to represent the total USA population.

The aim of the present study was to use a large population to evaluate the predictive role of ELNs, lymph node metastasis, and LNR in OS of pNENs after surgical resection. Furthermore, we attempted to establish the correlation between LNR and clinicopathological characteristics (tumor size, grade, and stage).

RESULTS {#s2}
=======

Patients' characteristics {#s2_1}
-------------------------

A total of 1,273 pathologically confirmed pNENs comprising of 680 males and 593 females, were included in our study (Figure [1](#F1){ref-type="fig"}). The median age and interquartile range (IQR) at diagnosis were 58 years (49 years--67 years). Approximately, 80% patients were ethnically Caucasians. The degree of tumor localized at the head was similar to that of the tail (32.8% and 36.8% of all patients, respectively, head-to-tail ratio, 0.89:1). Approximately, 60.0% of patients underwent partial pancreatectomy. The tumor size in 73.0% patients was larger than 2.0 cm. The median of ELNs was 10 (IQR, 5--16), and 42.0% patients with lymph node metastasis. The median of LNR was 0 (IQR, 0--0.2); 61.6% patients exhibited SEER grade I. The proportion of AJCC TNM stage I and stage II were 38.7% and 40.3%, respectively (Table [1](#T1){ref-type="table"}).

![Flowchart of patients selection process](oncotarget-08-89245-g001){#F1}

###### Clinicopathologic characteristics

                            Patients (*N* = 1273)   
  ------------------------- ----------------------- --------
  Age                                               
   ≤ 60 years               732                     57.50%
   \> 60 years              541                     42.50%
  Gender                                            
   Male                     680                     53.42%
   Female                   593                     46.58%
  Race                                              
   White                    1022                    80.28%
   Black                    131                     10.29%
   Others                   120                     9.43%
  Prime Site                                        
   Head                     417                     32.76%
   Body                     169                     13.28%
   Tail                     469                     36.84%
   Others                   218                     17.12%
  Surgical Procedures                               
   Enucleation              20                      1.57%
   Partial Pancreatectomy   736                     57.82%
   Total Pancreatectomy     136                     10.68%
   Whipple                  348                     27.34%
   Surgery NOS              33                      2.59%
  Size                                              
   ≤ 2 cm                   347                     27.26%
   \> 2 cm                  926                     72.74%
  Lymph Node                                        
   Negative                 742                     58.29%
   Positive                 531                     41.71%
  SEER Grade                                        
   I                        784                     61.59%
   II                       185                     14.53%
   III                      95                      7.46%
   IV                       16                      1.26%
   Unclear                  193                     15.16%
  AJCC stage 6th                                    
   I                        493                     38.73%
   II                       513                     40.30%
   III                      24                      1.89%
   IV                       243                     19.09%

NOS, not otherwise specified; SEER Grade \[[@R34]\]; AJCC, American Joint Committee on Cancer.

The lymph node metastasis and overall survival {#s2_2}
----------------------------------------------

As we assumed, the OS of the patients with lymph node metastasis (82.965 months ± 2.504 months) was significantly (*P* \< 0.001) shorter than that of patients without metastasis (97.615 months ± 2.086 months) (Figure [2A](#F2){ref-type="fig"}). The univariate analysis showed the lymph node metastasis significantly (*P* \< 0.001) increased the risk of death (HR 1.914, 95% CI: 1.467--2.497). However, the multivariate analysis failed to display that the lymph node metastasis was associated with OS (Table [2](#T2){ref-type="table"}).

![The Kaplan-Meier and log-rank tests of overall survival based on (**A**) lymph node metastasis; (**B**) the extent of examined lymph nodes of entire cohort; and (**C**) pNENs without lymph node metastasis.](oncotarget-08-89245-g002){#F2}

###### Univariate and multivariate Cox regression analysis (LNR cut-off value, 0 and 0.40)

  Variable                         *N*    Univariate     Multivariate                                             
  -------------------------------- ------ -------------- -------------- -------------- -------------- ----------- ------------------
  **Age**                                                                                                         
   ≤ 60 years                      732    reference      reference                                                
   **\> 60 years**                 541    \< 0.001       2.040          1.567--2.655   \< **0.001**   **2.186**   **1.665--2.871**
  **Gender**                                                                                                      
   Male                            680    reference      reference                                                
   **Female**                      593    0.003          0.663          0.507--0.868   **0.003**      **0.659**   **0.502--0.864**
  Race                                                                                                            
   White                           1022   reference                                                               
   Black                           131    0.457          0.840          0.530--1.331                              
   Other                           120    0.334          0.777          0.466--1.296                              
  **Site**                                                                                                        
   Head                            417    reference      reference                                                
   **Body**                        169    0.008          0.494          0.294--0.828   **0.008**      **0.492**   **0.290--0.833**
   **Tail**                        469    0.041          0.729          0.538--0.987   **0.031**      **0.710**   **0.519--0.970**
   Other                           218    0.163          0.768          0.530--1.113   0.180          0.768       0.522--1.130
  Surgical Procedures                                                                                             
   Enucleation                     20     reference                                                               
   PP                              736    0.413          0.618          0.196--1.952                              
   TP                              136    0.693          1.268          0.390--4.120                              
   Whipple                         348    0.846          1.121          0.354--3.549                              
   Surgery NOS                     33     0.341          0.483          0.108--2.161                              
  Tumor Size                                                                                                      
   ≤ 2 cm                          347    reference                                                               
   \> 2 cm                         926    0.006          1.650          1.155--2.358                              
  Lymph Node Metastasis                                                                                           
   Negative                        742    reference                                                               
   Positive                        531    \< 0.001       1.914          1.467--2.497                              
  Number of Examined Lymph Nodes                                                                                  
   ≤ 12                                   reference                                                               
   \> 12                                  0.074          1.276          0.977--1.667                              
  **SEER Grade**                                                                                                  
   I                               784    reference      reference                                                
   II                              185    0.491          1.166          0.754--1.802   0.623          1.118       0.718--1.740
   **III**                         95     **\<** 0.001   5.073          3.516--7.321   **\< 0.001**   **3.645**   **2.501--5.310**
   **IV**                          16     **\<** 0.001   4.071          1.886--8.789   **0.008**      **2.876**   **1.320--6.270**
   **Unknown**                     193    0.001          1.752          1.259--2.438   **0.003**      **1.665**   **1.193--2.324**
  **AJCC Stage 6th**                                                                                              
   I                               493                                  reference                                 
   II                              513    0.001          1.906          1.319--2.754   0.128          1.411       0.906--2.197
   **III**                         24     0.001          3.457          1.620--7.376   **0.008**      **2.933**   **1.325--6.490**
   **IV**                          243    \< 0.001       3.972          2.736--5.766   **\< 0.001**   **3.297**   **2.089--5.203**
  **Lymph Node Ratio**                                                                                            
   LNR = 0                         742    reference      reference                                                
   0 \< LNR ≤ 0.40                 369    0.001          1.665          1.233--2.249   0.621          1.095       0.765--1.567
   **LNR \> 0.40**                 162    \< 0.001       2.445          1.749--3.419   **0.012**      **1.650**   **1.117--2.438**

\*Only factor with *P*-value ≤ 0.05 was included in multivariate analysis; variable and *P*-value in bold mean statistically significant in multivariate analysis. PP, Partial Pancreatectomy; TP, Total Pancreatectomy; NOS, not otherwise specified; SEER Grade \[[@R34]\]; AJCC, American Joint Committee on Cancer.

The extent of examined lymph nodes and overall survival {#s2_3}
-------------------------------------------------------

The most appropriate cut-off value of ELNs for entire cohort and the patients without lymph node metastasis were 12 and 28, respectively. Surprisingly, we found that the extent of ELNs was not a significantly beneficial survival factor in either entire cohort (ELNs ≤ 12 vs. ELNs \> 12, 92.363 months ± 1.978 months vs. 85.285 months ± 2.582 months, *P =* 0.072) (Figure [2B](#F2){ref-type="fig"}) or in patients without lymph node metastasis (ELNs ≤ 28 vs. ELNs \> 28, 98.231 months ± 2.106 months vs. 72.246 months ± 9.734 months, *P =* 0.108) (Figure [2C](#F2){ref-type="fig"}).

The lymph node ratio and overall survival {#s2_4}
-----------------------------------------

The most appropriate cut-off value of LNR was 0.40 in our study; and we found that compared to the OS of patients with LNR = 0 (97.615 months ± 2.086 months) and 0 \< LNR ≤ 0.40 (86.468 months ± 3.006 months), LNR \> 0.40 exhibited significantly (*P* \< 0.001; *P* = 0.025; respectively) shorter OS (75.473 months ± 4.287 months) (Figure [3A](#F3){ref-type="fig"}). The multivariate analysis showed that LNR \> 0.40 was an independent prognostic factor (HR = 1.650, 95% CI: 1.117--2.438, *P* = 0.012) (Table [2](#T2){ref-type="table"}).

![The Kaplan-Meier and log-rank tests of overall survival based on different cut-off values of lymph node ratio](oncotarget-08-89245-g003){#F3}

We also evaluated the predictive role of LNR \> 0.2 and LNR \> 0.07 reported by Boninsegna et al. \[[@R19]\] and Ricci et al. \[[@R20]\], respectively. We found that compared to the OS of patients with LNR= 0 (97.615 months ± 2.086 months), patients with LNR \> 0.2 and LNR \> 0.07 presented significantly (both *P* \< 0.001) shorter OS (81.004 months ± 3.257 months and 82.245 months ± 2.648 months, respectively) (Figure [3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). The univariate analysis demonstrated that LNR \> 0.20 and LNR \> 0.07 significantly (both *P* \< 0.001) increased the risk of death (HR = 2.095, 95% CI: 1.561--2.812 and HR = 1.962, 95% CI: 1.496--2.574, respectively). However, the multivariate analysis failed to show that LNR \> 0.20 and LNR \> 0.07 were associated with OS ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

The independent prognostic factors and predictive power {#s2_5}
-------------------------------------------------------

Besides LNR \> 0.40, the multivariate analysis also confirmed that age \> 60 years (*P* \< 0.001), advanced SEER grade (grade III, *P* \< 0.001; grade IV, *P* = 0.008) and AJCC TNM staging (stage III, *P =* 0.008; stage IV, *P* \< 0.001) were the adverse predict factors of OS in pNENs; and female (*P* = 0.003), tumor located in body (*P* = 0.008) or tail (*P* = 0.031) were the beneficial factors. This prognosis model (age, gender, tumor primary site, SEER grade, AJCC TNM staging and LNR) had acceptable discrimination (Harrell's concordance index, 0.731, 95% CI: 0.689--0.773); and it was significantly better than SEER grade (Harrell's concordance index, 0.636, 95% CI: 0.597--0.676) or AJCC TNM staging (Harrell's concordance index, 0.636, 95% CI: 0.599--0.673).

The LNR and clinicopathological characteristics {#s2_6}
-----------------------------------------------

The Spearman's rank correlation showed a high LNR was positive correlated with an advanced AJCC TNM staging (r~s~ = 0.604, *P* \< 0.001). Similarly, the higher LNR showed positive correlation with bigger tumor size (r~s~ = 0.273, *P* \< 0.001) and advanced SEER grade (r~s~ = 0.136, *P* \< 0.001) (Table [3](#T3){ref-type="table"}).

###### Clinicopathological characters correlations with lymph node ratio (LNR)

  Variable             LNR = 0       0 \< LNR ≤ 0.4   LNR \> 0.4    *P*-value         r~s~
  -------------------- ------------- ---------------- ------------- ----------------- -----------
  **Tumor Size**                                                    **\< 0.001^&^**   **0.273**
  ≤ 2 cm               278 (37.5%)   55 (14.9%)       14 (8.6%)                       
  \> 2 cm              464 (62.5%)   314 (85.1%)      148 (91.4%)                     
  **SEER Grade**                                                    **\< 0.001^&^**   **0.136**
  I                    487 (65.6%)   219 (59.3%)      78 (48.1%)                      
  II                   108 (14.6%)   58 (15.7%)       19 (11.7%)                      
  III                  32 (4.3%)     41 (11.1%)       22 (13.6%)                      
  IV                   6 (0.8%)      7 (1.9%)         3 (1.9%)                        
  **AJCC stage 6th**                                                **\< 0.001^&^**   **0.604**
  I                    493 (66.4%)   0 (0%)           0 (0%)                          
  II                   166 (22.4%)   251 (68.0%)      96 (59.3%)                      
  III                  11 (1.5%)     9 (2.4%)         4 (2.5%)                        
  IV                   72 (9.7%)     109 (29.5%)      62 (38.3%)                      

SEER Grade \[[@R34]\]; AJCC, American Joint Committee on Cancer; ^&^Spearman's rank correlation, r~s~ correlation coefficient; Variable and *P*-value in bold mean statistically significant.

DISCUSSION {#s3}
==========

Currently, the AJCC and the European Neuroendocrine Tumor Society staging classification use the regional lymph node metastasis as a prognostic indicator of pNENs \[[@R21]\]. However, several studies proved contrary conclusions \[[@R22]--[@R25]\]. The conflicting results may be due to the incomplete lymphadenectomy or inadequate histopathological examination \[[@R26]\]. As the total number of ELNs rises, the number of metastatic lymph nodes also rises; and previous study demonstrated the number of ELNs were associated with the accuracy of lymph node staging and OS in PDAC, especially in patients without lymph node metastasis \[[@R15]\]. Thus, the International Study Group on Pancreatic Surgery recommended that at least 12 lymph nodes should be examined for PDAC \[[@R27]\].

In the present study, we only included patients underwent lymphadenectomy and the median of ELNs was 10 (IQR, 5--16). The most appropriate cut-off value of ELNs for entire cohort and pNENs without lymph node metastasis were 12 and 28, respectively. Surprisingly, we found the extent of ELNs failed to demonstrate any survival benefit in entire cohort (ELNs \> 12 vs. ELNs ≤ 12) or in the negative lymph node metastasis pNENs (ELNs \> 28 vs. ELNs ≤ 28). Similar to our findings, Conrad et al. \[[@R28]\] also demonstrated that the extent of ELNs (ELNs ≥ 10) failed to show significant survival advantage.

As mentioned by previous studies \[[@R7], [@R8]\], we also found the OS of pNENs with lymph node metastasis (82.965 months ± 2.504 months) was significantly (*P* \< 0.001) shorter than that of pNENs without lymph node metastasis (97.615 months ± 2.093 months). Moreover, the lymph node metastasis significantly (*P* \< 0.001) increased the risk of death (HR = 1.914; 95% CI: 1.467--2.497). However, the multivariate analysis failed to show lymph node metastasis was an independent prognostic factor in pNENs.

Recently, LNR has been demonstrated as a superior prognostic parameter than lymph node metastasis in PDAC \[[@R10], [@R11], [@R15]\], bladder \[[@R29]\], esophageal \[[@R30]\], and colon cancers \[[@R31]\]. Boninsegna et al. \[[@R19]\] and Ricci et al. \[[@R20]\] also demonstrated that LNR was an independent prognostic factor of recurrence in pNENs. However, Murakami et al. \[[@R8]\] reported LNR was not an independent prognostic factor of OS in pNENs.

We included 1,273 pathologically confirmed pNENs in our study and the most appropriate cut-off value of LNR was 0.40. The Kaplan-Meier and log-rank test demonstrated the OS of pNENs with LNR \> 0.40 (75.473 months ± 4.287 months) was significantly shorter than that of pNENs with LNR = 0 (97.615 months ± 2.086 months*, P* \< 0.001) and 0 \< LNR ≤ 0.40 (86.468 months ± 3.006 months, *P* = 0.025), respectively; not only the univariate analysis but also the multivariate analysis showed LNR was an independent prognostic factor. To our knowledge, the present study is the largest population-based study to assess the OS benefit of LNR in pNENs.

Ricci et al. \[[@R20]\] and Boninsegna et al. \[[@R19]\] reported LNR \> 0.07 and LNR \> 0.20 were independent adverse predictors of recurrence, respectively. However, they did not discuss the relationship between LNR and OS. We found that compared to LNR = 0, LNR \> 0.07 and LNR \> 0.20 also significantly (both *P* \< 0.001) increased the risk of death (HR = 1.962, 95% CI: 1.496--2.574; HR = 2.095, 95% CI: 1.561--2.812, respectively). However, the multivariate analysis failed to show LNR \> 0.07 or LNR \> 0.20 was an independent prognostic factor of OS. Our findings were consistent with those of Murakami et al. \[[@R8]\]. The authors reviewed the records of 119 consecutive patients with pancreatic ductal carcinoma and they also found LNR \> 0.2 was not an independent prognostic factor of OS.

In contrast to pNENs, several studies had demonstrated LNR \> 0.2 was an independent negative prognostic factor of OS in PDAC \[[@R32], [@R33]\]. The contradictory results can notably be explained by the relatively indolent physiological behavior of pNENs. pNENs are characterized by long term survival, even if lymph node metastases are present. Thus, the low cut-off value of LNR (0.20) may limit the identification of LNR in OS.

Besides LNR \> 0.40, age older than 60 years, advanced AJCC stage, and SEER grade, the multivariate Cox regressions also demonstrated that male and primary tumor located in pancreatic head were associated with poor outcome. This is probably due to that the carcinoid syndrome was more frequently in female patients; and this increased the likelihood of diagnosis and surgical treatment in the early lesions for female patients \[[@R34]\]. Hashim et al. \[[@R35]\] reported that compared to pancreas body or tail, the head was more likely associated with lymph node metastasis; and this can explain the adverse prognostic role of primary tumor located in pancreas head.

We also found that the higher LNR was positively correlated with bigger tumor size, advanced AJCC stage, and SEER grade. To our knowledge, this is the first study to investigate the correlation between LNR and clinicopathological features.

Notably, there were several limitations to our study. First, due to the constraints of the SEER database, we failed to evaluate the role of Ki-67, mitotic index, lymphovascular invasion, resection margin in OS. Second, this was a retrospective study; thus, the selection bias was inevitable.

In summary, our study demonstrated that it was LNR, not the number of ELNs or lymph node metastasis, proved to be an independent prognostic indicator. In the future, it is better to take into account the LNR for the pNENs staging classification; and further prospective study is needed to determine these findings.

MATERIALS AND METHODS {#s4}
=====================

Patient population {#s4_1}
------------------

To identify the pancreatic tumor, the topography codes (C25 Pancreas, C25.0-C25.9) of International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used. Then the pNEN cases were retrieved based on the following morphology codes: 8013 large cell neuroendocrine carcinoma, 8041 small cell carcinoma, 8150 islet cell carcinoma, 8151 malignant beta cell tumor, 8152 malignant alpha cell tumor, 8153 malignant gastrinoma, 8155 VIPoma, 8156 somatostatin cell tumor, 8157 malignant enteroglucagonoma, 8240 carcinoid, 8241 argentaffin carcinoid tumor, 8242 enterochromaffin cell tumor, 8243 mucocarcinoid tumor, 8246 neuroendocrine carcinoma, and 8249 atypical carcinoid tumor.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Only patients microscopically diagnosed as pNENs and underwent surgical resection were included. Cases without precise data for the following variables were excluded: race, tumor size, the number of lymph node metastasis or ELNs, and AJCC TNM staging. Large cell neuroendocrine carcinoma (ICD-O-3, 8013) and small cell carcinoma (ICD-O-3, 8041) mostly originating from lung were also excluded \[[@R3]\].

Outcome and variables {#s4_3}
---------------------

The primary outcome was OS and the following variables were considered as potential prognostic factors of OS: age; gender (male and female); race (white, black. other: American Indian/AK Native, Asian/Pacific Islander and unknown); primary tumor site (head, body, tail, other: islets of Langerhans, other specified parts of pancreas, overlapping lesion of pancreas, not otherwise specified); surgical procedures (enucleation, partial pancreatectomy, total pancreatectomy, whipple, surgery not otherwise specified); tumor size; lymph node metastasis; ELNs; LNR; SEER grade and AJCC TNM staging (sixth edition).

Not all of the SEER registries reported tumor grade according to the WHO 2010 classification \[[@R36]\]. Therefore, SEER database used four tumor grades based on the basis of morphological description (ICD-O-3) in pathology report: SEER grade I including tumors classified as well differentiated; grade II including those classified as moderately differentiated; grade III including those classified as poorly differentiated, and grade IV including those classified as undifferentiated or anaplastic \[[@R34]\].

The cut-off value of continuous variables {#s4_4}
-----------------------------------------

Age and tumor size were defined as two-category variable according to previous studies: age ≤ 60 years vs. age \> 60 years \[[@R23]\]; tumor size ≤ 2 cm vs. tumor size \> 2 cm \[[@R8]\]. The cut-off value of ELNs and LNR were determined according to the Youden's index \[[@R37]\]; and the ELNs were also analyzed as two-categories. We hypothesized that the lymph node metastasis was a prognostic factor of OS. Thus, the LNR was analyzed in three categories (LNR = 0, LNR between 0 and cut-off value; LNR \> cut-off value) and then it was also analyzed according to the cut-off value of 0.07 and 0.20 reported by Ricci et al. \[[@R20]\] and Boninsegna et al. \[[@R19]\], respectively.

Data analysis and statistics {#s4_5}
----------------------------

The continuous non-normal distribution variables were expressed as median and IQR, and the categorical or ordinal variables were presented as frequencies and proportions. The OS was analyzed using the Kaplan-Meier and log-rank tests and presented as mean ± standard deviation. Univariate (enter) and multivariate (forward stepwise regression) Cox proportional hazards models were used to identify the independent factors associated with OS. The Harrell's concordance index was used to evaluate the combined predictive power of all independent prognostic factors \[[@R38]\]. If the value is more than 0.70, it can be concluded that the model has an acceptable discriminatory capability \[[@R39]\]. Spearman's rank correlation coefficient, r~s~, was used to quantify the correlation between LNR and clinicopathological characteristics. r~s~ ranged from −1 to +1, where −1 indicates a perfect negative association of ranks, zero indicates no association between ranks and +1 refers to a perfect association of ranks. All statistical analyses were performed using SPSS version 19.0 (IBM Corporation. Armonk, NY, USA). *P*-value ≤ 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================
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